About
In situ chemovaccination
Areas of Focus
Categories
Drug Delivery & FormulationBoston & New England
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
3
As Collaborator
1
Total Enrollment
554
By Phase
PHASE3: 1PHASE2: 1NA: 1PHASE1/PHASE2: 1
By Status
COMPLETED: 2ACTIVE_NOT_RECRUITING: 1UNKNOWN: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT06263231Lead Sponsor
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
PHASE3Active, not recruiting
333 participants
Started: Jun 28, 2024 · Completed: Dec 31, 2028
NCT04781725Collaborator
INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer
PHASE2Unknown
90 participants
Started: Mar 25, 2021 · Completed: Mar 1, 2023
NCT04525456Lead Sponsor
Immune Responses With Reduxium
NACompleted
20 participants
Started: Oct 7, 2020 · Completed: Jan 27, 2021
NCT03058289Lead Sponsor
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
PHASE1/PHASE2Completed
111 participants
Started: Feb 9, 2017 · Completed: Feb 22, 2023
Locations (1)
Headquarters
Shelton, CT, United States
Map
Loading map...